share_log

INVO Bioscience | 8-K: INVO Reports Record First Quarter 2024 Financial Results 353% Revenue Growth with improvement in Adjusted EBITDA

SEC ·  May 16, 2024 04:57
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.